Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903771 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
A Phase 1 study, sponsored by Kazia Therapeutics Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02903771 is a Phase 1 study that has completed, run by Kazia Therapeutics Limited. The registered enrollment target is 32 participants.
The verdict
NCT02903771, a Phase 1 study, has completed, sponsored by Kazia Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the safety and feasibility of weekly intra-peritoneal administration of Cantrixil to women with persistent or recurrent ovarian cancer, Fallopian tube cancer or primary peritoneal cancer. The study also aims to determine the maximum tolerated dose of Cantrixil in these patients when administered as a monotherapy or a combination therapy.
Interventions
- DRUG Part A: Dose Escalation of Cantrixil
- DRUG Part B: Expansion Cohort of Cantrixil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-12-05 |
| Est. Completion | 2020-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02903771
The ClinicalTrials.gov registry entry for NCT02903771 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kazia Therapeutics Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Part A: Dose Escalation of Cantrixil is the first listed.
NCT02903771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02903771 about?
NCT02903771 is a clinical study titled "Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.". The main purpose of this study is to determine the safety and feasibility of weekly intra-peritoneal administration of Cantrixil to women with persistent or recurrent ovarian cancer, Fallopian tube cancer or primary peritoneal cancer. The study also aims to determine the maximum tolerated dose of Ca...
What is the current status of trial NCT02903771?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-12-05. Estimated completion is 2020-03-24.
What interventions are being tested in trial NCT02903771?
The interventions under investigation include: Part A: Dose Escalation of Cantrixil (DRUG), Part B: Expansion Cohort of Cantrixil (DRUG).
Who is sponsoring clinical trial NCT02903771?
This trial is sponsored by Kazia Therapeutics Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.